Exercise For Fighting Oncology Repercussions After Treatment - Trial NCT05980325
Access comprehensive clinical trial information for NCT05980325 through Pure Global AI's free database. This phase not specified trial is sponsored by Universitat Pompeu Fabra and is currently Not yet recruiting. The study focuses on Neoplasms. Target enrollment is 45 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Universitat Pompeu Fabra
Timeline & Enrollment
N/A
Jan 01, 2024
Jul 01, 2025
Primary Outcome
Health-Related Quality of Life
Summary
Cancer survival rates are currently on the verge of 70% at 5 years since diagnosis. Recent
 improvements in main cancer therapies including chemotherapy, radiotherapy, surgery and
 immunotherapy as well as developments of new biological therapies have significantly improved
 survival rates but unfortunately, cancer-related side effects continue to affect many
 patients even years after completion of main treatments. Exercise has been shown to not only
 ameliorate cancer-related effects before, during and after treatment but also improve
 disease-free and overall survival rates by decreasing risk factors associated with cancer
 risk and improving resilience to treatment. In this non-randomised, three-arm study, we aim
 to assess the effects of three forms of exercise (i.e: Nordic Walking, Aquatic Exercise and
 Functional Exercise) on physical performance, cancer-related fatigue, health-related quality
 of life and cancer-specific symptoms in a wide range of cancer survivors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05980325
Non-Device Trial